Stat5−/− CD4+ T cells elicit anti-melanoma effect by CD4+ T cell remolding and Notch1 activation

• Published in: Science China. Life sciences 2022-09, Vol.65 (9), p.1824-1839
• Main Authors: Jin, Ke, Li, Tong, Miao, Zhiyong, Ran, Jingjing, Chen, Luyu, Mou, Dachao, Wang, Chuang, Wu, Shasha, Yang, Hanshuo, Fu, Xin-Yuan
• Format: Article
• Language: English
• Subjects: Antitumor activity; Biomedical and Life Sciences; CD4 antigen; Cell activation; Cell differentiation; Helper cells; Immunotherapy; Life Sciences; Lymphocytes; Lymphocytes T; Melanoma; Metastases; Notch1 protein; Research Paper; Stat5 protein; Transcription factors; Tumor-infiltrating lymphocytes; γ-Interferon
• ISSN: 1674-7305; 1869-1889
• DOI: 10.1007/s11427-021-2078-6

Signal transducers and activators of transcription 5 (Stat5) is known to engage in regulating the differentiation and effector function of various subsets of T helper cells. However, how Stat5 regulates the antitumor activity of tumor-infiltrating CD4 + T cells is largely unknown. Here, we showed that mice with specific deletion of Stat5 in CD4 + T cells were less susceptible to developing subcutaneous and lung metastatic B16 melanoma with CD4 + tumor-infiltrating lymphocytes (TILs) remolding. Especially, we confirmed that Stat5-deficient CD4 + naïve T cells were prone to polarization of two subtypes of Th17 cells: IFN-γ + and IFN-γ − Th17 cells, which exhibited increased anti-melanoma activity through enhanced activation of Notch1 pathway compared with wild type Th17 cells. Our study therefore revealed a novel function of Stat5 in regulating tumor-specific Th17 cell differentiation and function in melanoma. This study also provided a new possibility for targeting Stat5 and other Th17-associated pathways to develop novel immunotherapies for melanoma patients.